Kim Stanley E, Pozzi Antonio, Yeh Jiunn-Chern, Lopez-Velazquez Mariana, Au Yong Jo Anne, Townsend Sarah, Dunlap Anna E, Christopher Scott A, Lewis Daniel D, Johnson Matthew D, Petrucci Kathryn
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, United States.
Animal Cell Therapies, San Diego, CA, United States.
Front Vet Sci. 2019 Dec 20;6:474. doi: 10.3389/fvets.2019.00474. eCollection 2019.
Intra-articular stem cell therapy may help alleviate lameness caused by osteoarthritis in dogs. Umbilical cord-derived stem cell (UMSC) therapy has not yet been investigated in a veterinary clinical study. We hypothesized that dogs treated with intra-articular UMSC will have improved limb function and quality of life when compared to dogs treated with a saline placebo injection. This was a prospective, double-blinded, placebo-controlled clinical trial in client-owned dogs with chronic elbow osteoarthritis with a follow-up time of 6 months. Dogs were assigned to receive intra-articular UMSC ( = 38) or a saline placebo intra-articular injection ( = 30). Outcome measures included the Canine Brief Pain Inventory score (CBPI) and peak vertical force (PVF) from force-platform gait analysis. Treatment was considered successful when there was a decrease in the Pain Severity Score of at least one and a decrease in the Pain Interference Score of at least one from baseline. Success rates and PVF were compared between groups. No adverse effects associated with UMSC were noted. Of the dogs completing the study, treatment success in the UMSC ( = 28) vs. placebo groups ( = 23) was observed in 54 vs. 28% of dogs at 1 month, 50 vs. 27% at 3 months, and 46 vs. 14% at 6 months, respectively. Success rate in the UMSC group was significantly higher than the placebo group at 1 and 6 months after treatment. However, no differences in PVF of the affected limb over time was observed in either group. Intra-articular UMSC for osteoarthritis may improve clinical signs based on owner observations.
关节内干细胞疗法可能有助于减轻犬类骨关节炎引起的跛行。脐带间充质干细胞（UMSC）疗法尚未在兽医临床研究中得到研究。我们假设，与接受生理盐水安慰剂注射治疗的犬相比，接受关节内UMSC治疗的犬的肢体功能和生活质量将得到改善。这是一项针对患有慢性肘关节骨关节炎的宠物犬的前瞻性、双盲、安慰剂对照临床试验，随访时间为6个月。犬被分配接受关节内UMSC（n = 38）或生理盐水安慰剂关节内注射（n = 30）。结果指标包括犬简短疼痛量表评分（CBPI）和力平台步态分析中的垂直峰值力（PVF）。当疼痛严重程度评分至少降低1分且疼痛干扰评分至少比基线降低1分时，治疗被认为是成功的。比较两组之间的成功率和PVF。未观察到与UMSC相关的不良反应。在完成研究的犬中，UMSC组（n = 28）与安慰剂组（n = 23）的治疗成功率在1个月时分别为54%和28%，3个月时为50%和27%，6个月时为46%和14%。治疗后1个月和6个月，UMSC组的成功率显著高于安慰剂组。然而，两组中患侧肢体的PVF随时间均未观察到差异。基于主人的观察，关节内注射UMSC治疗骨关节炎可能会改善临床症状。
